|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing cisplatin to carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Belli C, Fennell D, Giovannini M, Gaudino
G and Mutti L: Malignant pleural mesothelioma: current treatments
and emerging drugs. Expert Opin Emerg Drugs. 14:423–437. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, Niyikiza C and Paoletti P: Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol.
21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S,
Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara
D: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naïve patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008.PubMed/NCBI
|
|
6
|
Hong J, Kyung SY, Lee SP, Park JW, Jung
SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB and Lee JH:
Pemetrexed versus gefitinib versus erlotinib in previously treated
patients with non-small cell lung cancer. Korean J Intern Med.
25:294–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shih C, Chen VJ, Gossett LS, Gates SB,
MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ,
Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP,
Kohler W, Ratnam M and Schultz RM: LY231514, a
pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple
folate-requiring enzymes. Cancer Res. 57:1116–1123. 1997.
|
|
8
|
Park CK, Kim KS, Oh IJ, Tseden-Ish M, Choi
YD, Kwon YS, Kim YI, Lim SC and Kim YC: Efficacy of pemetrexed in
relapsed non-small cell lung cancer and thymidylate synthase
expression. Tuberc Respir Dis. 67:191–198. 2009. View Article : Google Scholar
|
|
9
|
Ramirez JM, Ocio EM, San Miguel JF and
Pandiella A: Pemetrexed acts as an antimyeloma agent by provoking
cell cycle blockade and apoptosis. Leukemia. 21:797–804.
2007.PubMed/NCBI
|
|
10
|
Lu X, Errington J, Curtin NJ, Lunec J and
Newell DR: The impact of p53 status on cellular sensitivity to
antifolate drugs. Clin Cancer Res. 7:2114–2123. 2001.PubMed/NCBI
|
|
11
|
Vandermeers F, Hubert P, Delvenne P,
Mascaux C, Grigoriu B, Burny A, Scherpereel A and Willems L:
Valproate, in combination with pemetrexed and cisplatin, provides
additional efficacy to the treatment of malingnant mesothelioma.
Clin Cancer Res. 15:2818–2828. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.
|
|
14
|
Demierre MF, Higgins PD, Gruber SB, Hawk E
and Lippman SM: Statins and cancer prevention. Nat Rev Cancer.
5:930–942. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Holstein SA and Hohl RJ: Synergistic
interaction of lovastatin and paclitaxel in human cancer cells. Mol
Cancer Ther. 1:141–149. 2001.PubMed/NCBI
|
|
16
|
Feleszko W, Mlynarczuk I, Olszewska D,
Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G and
Jakobisiak M: Lovastatin potentiates antitumor activity of
doxorubicin in murine melanoma via an apoptosis-dependent
mechanism. Int J Cancer. 100:111–118. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khanzada UK, Pardo OE, Meier C, Downward
J, Seckl MJ and Arcaro A: Potent inhibition of small-cell lung
cancer cell growth by simvastatin reveals selective functions of
Ras isoforms in growth factor signaling. Oncogene. 25:877–887.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kozar K, Kaminski R, Legat M, Kopec M,
Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J:
Cerivastatin demonstrates enhanced antitumor activity against human
breast cancer cell lines when used in combination with doxorubicin
or cisplatin. Int J Oncol. 24:1149–1157. 2004.
|
|
19
|
Hwang KE, Park C, Kwon SJ, Kim YS, Park
DS, Lee MK, Kim BR, Park SH, Yoon KH, Jeong ET and Kim HR:
Synergistic induction of apoptosis by sulindac and simvastatin in
A549 human lung cancer cells via reactive oxygen species-dependent
mitochondrial dysfunction. Int J Oncol. 43:262–270. 2013.PubMed/NCBI
|
|
20
|
Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI,
Lee JH, Lee CT and Lee JS: Efficacy and toxicity of pemetrexed as a
third-line treatment of non-small cell lung cancer. Jpn J Clin
Oncol. 39:27–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim KH, Song SY, Lim KH, Han SS, Kim SH,
Cho JH, Park CW, Lee S and Lee HY: Interstitial pneumonitis after
treatment with pemetrexed for non-small cell lung cancer. Cancer
Res Treat. 45:74–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wolf CM and Eastman A: The temporal
relationship between protein phosphatase, mitochondrial cytochrome
c release. Exp Cell Res. 247:505–513. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschi T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prevost GP, Pradines A, Brezak MC,
Lonchampt MO, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T,
Favre G and Morgan B: Inhibition of human tumor cell growth in vivo
by an orally bioavailable inhibitor of human farnesyltransferase,
BIM-46228. Int J Cancer. 91:718–722. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song JY, Kim CS, Lee JH, Jang SJ, Lee SW,
Hwang JJ, Lim C, Lee G, Seo J, Cho SY and Choi J: Dual inhibition
of MEK 1/2 and EGFR synergistically induces caspase-3-dependent
apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM
upregulation. Invest New Drugs. 31:1458–1465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schulze-Bergkamen H and Krammer PH:
Apotosis in cancer-implications for therapy. Semin Oncol.
31:90–119. 2004. View Article : Google Scholar
|
|
27
|
Copeland WC, Wachsman JT, Johnson FM and
Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest.
20:557–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HR, Yang SH and Jeong ET: Combination
treatment with arsenic trioxide and sulindac induces apoptosis of
NCI-H157 human lung carcinoma cells via ROS generation with
mitochondrial dysfunction. Tuberc Respir Dis. 59:30–38. 2005.
|
|
29
|
Frank S, Gaume B, Bergmann-Leitner ES,
Leitner WW, Robert EG, Catez F, Smith CL and Youle RJ: The role of
dynamic-related protein 1, a mediator of mitochondrial fission, in
apoptosis. Dev Cell. 1:515–525. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karbowski M, Lee YJ, Gaume B, Jeong SY,
Frank S, Nechushtan A, Santel A, Fuller M, Smith CL and Youle RJ:
Spatial and temporal association of Bax with mitochondrial fission
sites, Drp1, and Mfn2 during apoptosis. J Cell Biol. 159:931–938.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
|
|
32
|
Li LY, Luo X and Wang X: Endonuclease G is
an apoptotic DNase when released from mitochondria. Nature.
412:95–99. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tournier C, Hess P, Yang DD, Xu J, Turner
TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA and Davis RJ:
Requirement of JNK for stress-induced activation of the cytochrome
c-mediated death pathway. Science. 288:870–874. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burdon RH: Control of cell proliferation
by reactive oxygen species. Biochem Soc Trans. 24:1028–1032.
1996.PubMed/NCBI
|
|
35
|
Buque A, Muhialdin JSh, Munoz A, Calvo B,
Carrera S, Aresti U, Sancho A, Rubio I and Lopez-Vivinco G:
Molecular mechanism implicated in pemetrexed-induced apoptosis in
human melanoma cells. Mol Cancer. 11:252012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fiers W, Beyaert R, Declercq W and
Vandenabeele P: More than one way to die: apoptosis, necrosis and
reactive oxygen damage. Oncogene. 18:7719–7730. 1999. View Article : Google Scholar
|
